The Department of Health and Human Services announced a new policy granting enforcement discretion for six peptides currently available on the gray market, permitting small compounding pharmacies to manufacture them without federal intervention. The decision aligns with the position of Health Secretary Robert F. Kennedy Jr., who has publicly supported broader access to peptides and stated personal use of them.
Peptides are chains of amino acids shorter than proteins that can produce significant physiological effects. While some occur naturally, others are synthetic variants. Despite widespread promotion by wellness influencers and certain clinicians for various health applications, evidence supporting their safety and efficacy remains limited. The peptides have not undergone the FDA’s standard drug approval process.
In July, an FDA advisory panel voted to support expanded access to the six peptides through compounding pharmacies, though the FDA’s own scientific staff recommended against removing existing restrictions. The new policy frames compounded versions as safer alternatives to illicit peptides sold online from questionable overseas sources. However, the policy applies only to smaller 503A compounding pharmacies, not larger 503B outsourcing facilities, potentially creating supply challenges. Industry representatives acknowledge that existing compounders may struggle to meet consumer demand, with some stating they could produce only limited quantities of select peptides after facility preparations.
Pharmacy industry groups expressed support, noting the policy provides regulatory oversight and adverse event reporting mechanisms compared to unregulated gray market access. However, consumer advocacy organizations raised concerns. Public Citizen argued that the decision undermines FDA authority and bypassed standard rulemaking procedures, urging clinicians to educate patients about contamination risks. The Partnership for Safe Medicines filed a petition opposing the advisory committee recommendation, citing insufficient evidence of safety and the FDA scientists’ cautionary recommendation.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI